Agenus/$AGEN
14:30
16:10
17:45
19:25
21:00
1D1W1MYTD1Y5YMAX
About Agenus
Agenus Inc is an American clinical-stage company with a pipeline of therapies designed to activate the body's immune system to fight cancer and infections, including immune-modulatory antibodies, adoptive cell therapies through its subsidiary MiNK Therapeutics Inc. and vaccine adjuvants through its subsidiary SaponiQx Inc. This robust product pipeline is supported by company's in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. The company's antibody candidates are botensilimab (a proprietary next-generation Fc-engineered CTLA-4 antibody, also known as AGEN1811) and balstilimab (a PD-1 antibody).
Ticker
$AGEN
Sector
Primary listing
Employees
316
Headquarters
Website
Agenus Metrics
BasicAdvanced
$127M
-
-$1.32
1.51
-
Price and volume
Market cap
$127M
Beta
1.51
52-week high
$7.34
52-week low
$1.38
Average daily volume
500K
Financial strength
Current ratio
0.467
Quick ratio
0.034
Long term debt to equity
-12.233
Total debt to equity
-16.43
Interest coverage (TTM)
-1.00%
Profitability
EBITDA (TTM)
-50.279
Gross margin (TTM)
0.08%
Net profit margin (TTM)
-32.92%
Operating margin (TTM)
-58.92%
Revenue per employee (TTM)
$340,000
Management effectiveness
Return on assets (TTM)
-16.66%
Return on equity (TTM)
14.21%
Valuation
Price to revenue (TTM)
0.935
Price to book
-0.45
Price to tangible book (TTM)
-0.41
Price to free cash flow (TTM)
-1.119
Free cash flow yield (TTM)
-89.36%
Free cash flow per share (TTM)
-3.324
Growth
Revenue change (TTM)
-33.41%
Earnings per share change (TTM)
-88.13%
3-year revenue growth (CAGR)
5.92%
10-year revenue growth (CAGR)
18.98%
3-year earnings per share growth (CAGR)
-56.45%
10-year earnings per share growth (CAGR)
-26.10%
What the Analysts think about Agenus
Analyst ratings (Buy, Hold, Sell) for Agenus stock.
Agenus Financial Performance
Revenues and expenses
Agenus Earnings Performance
Company profitability
Agenus News
AllArticlesVideos
Agenus to Host End-of-Year Stakeholder Webcast Featuring GI Oncology Leaders and Progress of BOT/BAL
Business Wire·4 weeks ago
Agenus Appoints Dr. José Iglesias as Chief Medical Affairs Officer to Guide Global Medical Affairs and Early-Access Programs, Including France's AAC
Business Wire·4 weeks ago
Agenus Reports Q3 2025 Results Showcasing Clinical and Regulatory Advances
Business Wire·1 month ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.
Capital at risk
Upcoming events
No upcoming events
FAQs
What’s the current market cap for Agenus stock?
Agenus (AGEN) has a market cap of $127M as of December 17, 2025.
What is the P/E ratio for Agenus stock?
The price to earnings (P/E) ratio for Agenus (AGEN) stock is 0 as of December 17, 2025.
Does Agenus stock pay dividends?
No, Agenus (AGEN) stock does not pay dividends to its shareholders as of December 17, 2025.
When is the next Agenus dividend payment date?
Agenus (AGEN) stock does not pay dividends to its shareholders.
What is the beta indicator for Agenus?
Agenus (AGEN) has a beta rating of 1.51. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.